Abbott Laboratories (ABT)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $187.95B
Last updated: Nov 17, 2026 at 11:05 AM ET
Abbott Laboratories (ABT) Financials: Revenue, Profit and Cash Flow
Abbott Laboratories reported revenue of $44.33B for the fiscal year ended Dec 31, 2025, up 5.7% from the year before. That year, net income was $6.52B with a net margin of 14.7%, operating cash flow was $9.57B and free cash flow was $7.39B. The quarter ended Sep 30, 2026 had revenue of $13.01B and net income of $920.00M.
Revenue and Margins
The operating margin was 18.2% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $20.85B, a compound annual rate of 8.7%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $44.33B | +5.7% | 56.4% | 18.2% | 14.7% |
| Dec 2024 | $41.95B | +4.6% | 55.4% | 16.3% | 31.9% |
| Dec 2023 | $40.11B | -8.1% | 55.2% | 16.2% | 14.3% |
| Dec 2022 | $43.65B | +1.3% | 56.1% | 19.2% | 15.9% |
| Dec 2021 | $43.08B | +24.5% | 57.0% | 19.6% | 16.4% |
| Dec 2020 | $34.61B | +8.5% | 56.6% | 15.5% | 13.0% |
| Dec 2019 | $31.90B | +4.3% | 58.5% | 14.2% | 11.6% |
| Dec 2018 | $30.58B | +11.6% | 58.4% | 11.9% | 7.7% |
| Dec 2017 | $27.39B | +31.3% | 54.7% | 5.7% | 1.7% |
| Dec 2016 | $20.85B | N/A | 56.4% | 14.5% | 6.7% |
Income Statement
In the fiscal year ended Dec 2025, net income fell 51.3% from the year before. In the quarter ended Sep 2026, net income fell 43.9% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.33B | $41.95B | $40.11B | $43.65B | $43.08B | $34.61B | $31.90B | $30.58B | $27.39B | $20.85B |
| Cost of revenue | $19.32B | $18.71B | $17.98B | $19.14B | $18.54B | $15.00B | $13.23B | $12.71B | $12.41B | $9.09B |
| Gross profit | $25.01B | $23.24B | $22.13B | $24.51B | $24.54B | $19.61B | $18.67B | $17.87B | $14.98B | $11.76B |
| Research and development | $2.94B | $2.84B | $2.74B | $2.89B | $2.74B | $2.42B | $2.44B | $2.30B | $2.26B | $1.45B |
| Operating income | $8.05B | $6.83B | $6.48B | $8.36B | $8.43B | $5.36B | $4.53B | $3.65B | $1.56B | $3.03B |
| Net income | $6.52B | $13.40B | $5.72B | $6.93B | $7.07B | $4.50B | $3.69B | $2.37B | $477.00M | $1.40B |
| EBITDA | $11.77B | $10.45B | $10.16B | $11.95B | $12.24B | $8.79B | $7.73B | $7.07B | $6.94B | $3.26B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $13.01B | $12.59B | $11.16B | $11.46B | $11.37B | $11.14B | $10.36B | $10.97B | $10.63B | $10.38B | $9.96B | $10.24B |
| Gross profit | $7.38B | $7.27B | $6.27B | $6.54B | $6.29B | $6.29B | $5.89B | $6.03B | $5.94B | $5.77B | $5.50B | $5.68B |
| Operating income | $1.36B | $1.69B | $1.34B | $2.25B | $2.06B | $2.05B | $1.69B | $1.91B | $1.86B | $1.67B | $1.39B | $1.78B |
| Net income | $920.00M | $928.00M | $1.08B | $1.78B | $1.64B | $1.78B | $1.32B | $9.23B | $1.65B | $1.30B | $1.23B | $1.59B |
Balance Sheet
As of Dec 2025, total debt of $12.93B exceeded cash and equivalents by $4.41B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $86.71B | $81.41B | $73.21B | $74.44B | $75.20B | $72.55B | $67.89B | $67.17B | $76.25B | $52.67B |
| Current assets | $26.00B | $23.66B | $22.67B | $25.22B | $24.24B | $20.44B | $15.67B | $14.63B | $20.15B | $26.78B |
| Cash and equivalents | $8.52B | $7.62B | $6.90B | $9.88B | $9.80B | $6.84B | $3.86B | $3.84B | $9.41B | $18.62B |
| Total liabilities | $33.94B | $33.51B | $34.39B | $37.53B | $39.17B | $39.55B | $36.59B | $36.45B | $45.15B | $31.95B |
| Short-term debt | $3.03B | $1.50B | $1.08B | $2.25B | $754.00M | $220.00M | $1.48B | $207.00M | $714.00M | $1.32B |
| Long-term debt | $9.90B | $12.63B | $13.60B | $14.52B | $17.30B | $18.53B | $16.66B | $19.36B | $27.21B | $20.68B |
| Shareholder equity | $52.13B | $47.66B | $38.60B | $36.69B | $35.80B | $32.78B | $31.09B | $30.52B | $30.90B | $20.54B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $108.25B | $109.22B | $110.43B | $86.71B | $84.18B | $84.00B | $81.45B | $81.41B | $74.36B | $73.02B | $72.47B | $73.21B |
| Total liabilities | $56.62B | $57.45B | $57.73B | $33.94B | $32.92B | $33.17B | $32.38B | $33.51B | $34.33B | $33.46B | $33.42B | $34.39B |
| Cash and equivalents | $4.05B | $5.10B | $6.80B | $8.52B | $7.51B | $6.95B | $6.53B | $7.62B | $7.56B | $6.99B | $6.28B | $6.90B |
| Shareholder equity | $51.03B | $51.11B | $52.06B | $52.13B | $50.95B | $50.56B | $48.81B | $47.66B | $39.80B | $39.32B | $38.81B | $38.60B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 77.2% of operating cash flow. Dividends and share repurchases together came to 67.8% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $9.57B | $8.56B | $7.26B | $9.58B | $10.53B | $7.90B | $6.14B | $6.30B | $5.57B | $3.20B |
| Capital expenditures | $2.17B | $2.21B | $2.20B | $1.78B | $1.89B | $2.18B | $1.64B | $1.39B | $1.14B | $1.12B |
| Free cash flow | $7.39B | $6.35B | $5.06B | $7.80B | $8.65B | $5.72B | $4.50B | $4.91B | $4.43B | $2.08B |
| Dividends paid | $4.12B | $3.84B | $3.56B | $3.31B | $3.20B | $2.56B | $2.27B | $1.97B | $1.85B | $1.54B |
| Share repurchases | $893.00M | $1.29B | $1.23B | $3.79B | $2.30B | $403.00M | $718.00M | $238.00M | $117.00M | $522.00M |
| Investing cash flow | -$2.42B | -$2.34B | -$3.13B | -$1.74B | -$2.01B | -$2.21B | -$1.81B | -$1.36B | -$9.62B | -$248.00M |
| Financing cash flow | -$6.31B | -$5.40B | -$7.09B | -$7.64B | -$5.49B | -$2.78B | -$4.29B | -$10.39B | -$5.28B | $11.15B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.74B | $2.49B | $1.31B | $3.31B | $2.79B | $2.05B | $1.42B | $2.87B | $2.71B | $1.96B | $1.02B | $3.04B |
| Capital expenditures | $513.00M | $497.00M | $399.00M | $689.00M | $496.00M | $502.00M | $484.00M | $720.00M | $556.00M | $533.00M | $398.00M | $755.00M |
| Free cash flow | $1.22B | $1.99B | $916.00M | $2.63B | $2.29B | $1.54B | $933.00M | $2.15B | $2.15B | $1.43B | $627.00M | $2.28B |
Frequently Asked Questions About ABT
What is Abbott Laboratories' annual revenue?
Abbott Laboratories reported revenue of $44.33B for the fiscal year ended Dec 31, 2025.
How fast is Abbott Laboratories' revenue growing?
Revenue was up 5.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 0.5%.
Is Abbott Laboratories profitable?
Yes. Abbott Laboratories reported net income of $6.52B for the fiscal year ended Dec 31, 2025, with a net margin of 14.7%.
How much free cash flow does ABT generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $9.57B minus capital expenditures of $2.17B produced free cash flow of $7.39B.
How much debt does Abbott Laboratories have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $9.90B, short-term debt of $3.03B and cash and equivalents of $8.52B.
ABT pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts